Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 6,800 shares, a decline of 40.4% from the November 15th total of 11,400 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 610,700 shares, the short-interest ratio is currently 0.0 days.
Bluejay Diagnostics Stock Performance
Shares of NASDAQ BJDX remained flat at $4.10 during mid-day trading on Thursday. 16,400 shares of the company were exchanged, compared to its average volume of 176,480. The stock has a 50-day simple moving average of $4.71 and a 200 day simple moving average of $40.15. The stock has a market cap of $2.27 million, a PE ratio of 0.00 and a beta of 0.70. Bluejay Diagnostics has a 1 year low of $3.03 and a 1 year high of $1,372.00.
Institutional Investors Weigh In On Bluejay Diagnostics
An institutional investor recently raised its position in Bluejay Diagnostics stock. Anson Funds Management LP raised its holdings in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) by 359.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the quarter. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 18.47% of the company’s stock.
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Read More
- Five stocks we like better than Bluejay Diagnostics
- The 3 Best Retail Stocks to Shop for in August
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- How to Invest in Insurance Companies: A Guide
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Intel Stock: A Value Play in the Quantum Computing Space
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.